ADMA Biologics, Inc.

NasdaqGM:ADMA Stock Report

Market Cap: US$4.1b

ADMA Biologics Future Growth

Future criteria checks 4/6

ADMA Biologics is forecast to grow earnings and revenue by 30.5% and 18.1% per annum respectively while EPS is expected to grow by 28.9% per annum.

Key information

30.5%

Earnings growth rate

28.9%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate18.1%
Future return on equityn/a
Analyst coverage

Low

Last updated17 Dec 2024

Recent future growth updates

ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next

May 13
ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next

Recent updates

ADMA Biologics: Capitalizing On A $20 Billion IG Market With ASCENIV

Dec 02

Subdued Growth No Barrier To ADMA Biologics, Inc. (NASDAQ:ADMA) With Shares Advancing 36%

Nov 26
Subdued Growth No Barrier To ADMA Biologics, Inc. (NASDAQ:ADMA) With Shares Advancing 36%

ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues

Oct 09
ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues

ADMA Biologics: Riding High On ASCENIV's Success

Oct 02

ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price

Sep 06
ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price

ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality

Aug 16
ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality

ADMA Biologics: A Compelling GARP Stock For Biotech Investors

Jul 27

ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Jul 24
ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?

Jul 17
Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?

Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?

May 30
Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?

ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next

May 13
ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next

Giving ADMA Biologics A Well-Deserved 'Booyah'

May 12

ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares

May 08
ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares

Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?

Apr 04
Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?

Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)

Apr 03

ADMA Biologics: On A Roll Entering 2024

Jan 19

Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?

Jan 09
Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?

ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Jan 09
ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Oct 25
We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Jun 10
We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet

May 12
The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet

ADMA Biologics: Strong Growth Is Clearing The Path To Profitability

Aug 21

ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M

Aug 10

ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

Jun 01
ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

ADMA Biologics: A Path To Profits Looks Clear

May 12

ADMA: Pertinent Updates

Apr 18

ADMA Biologics' 2021 Numbers Showed Continued Strong Execution

Mar 29

Earnings and Revenue Growth Forecasts

NasdaqGM:ADMA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20265792192362284
12/31/20254851761081764
12/31/2024422124411134
9/30/2024383687986N/A
6/30/2024330356673N/A
3/31/2024283-41621N/A
12/31/2023258-2849N/A
9/30/2023234-23-23-16N/A
6/30/2023208-40-51-41N/A
3/31/2023182-48-61-48N/A
12/31/2022154-66-73-60N/A
9/30/2022130-70-99-86N/A
6/30/2022110-73-99-86N/A
3/31/202294-78-119-105N/A
12/31/202181-72-126-112N/A
9/30/202169-74-125-111N/A
6/30/202158-74-135-122N/A
3/31/202148-75-124-111N/A
12/31/202042-76-115-102N/A
9/30/202040-67-100-89N/A
6/30/202037-61-99-89N/A
3/31/202036-54-92-87N/A
12/31/201929-48-80-76N/A
9/30/201921-56-78-75N/A
6/30/201918-59-66-64N/A
3/31/201916-61-62-61N/A
12/31/201817-66-65-63N/A
9/30/201818-61-61-57N/A
6/30/201818-61N/A-54N/A
3/31/201817-55N/A-48N/A
12/31/201716-44N/A-37N/A
9/30/201714-35N/A-28N/A
6/30/201712-24N/A-22N/A
3/31/201711-21N/A-18N/A
12/31/201611-20N/A-18N/A
9/30/201610-20N/A-19N/A
6/30/20169-20N/A-17N/A
3/31/20168-19N/A-16N/A
12/31/20157-18N/A-15N/A
9/30/20156-17N/A-14N/A
6/30/20156-15N/A-14N/A
3/31/20156-15N/A-14N/A
12/31/20146-17N/A-15N/A
9/30/20145-18N/A-15N/A
6/30/20145-17N/A-15N/A
3/31/20144-18N/A-13N/A
12/31/20133-16N/A-11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ADMA's forecast earnings growth (30.5% per year) is above the savings rate (2.6%).

Earnings vs Market: ADMA's earnings (30.5% per year) are forecast to grow faster than the US market (15.2% per year).

High Growth Earnings: ADMA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ADMA's revenue (18.1% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: ADMA's revenue (18.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ADMA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 07:58
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ADMA Biologics, Inc. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristen KluskaCantor Fitzgerald & Co.
Sheshadri N.Crisp Idea
Raghuram SelvarajuH.C. Wainwright & Co.